Abstract：
BACKGROUND: Recently, our group introduced Stroma AReactive Invasion Front Areas (SARIFA) as an independent prognostic predictor for a poorer outcome in colon cancer patients, which is probably based on immunologic alterations combined with a direct tumor-adipocyte interaction: the two together reflecting a distinct tumor biology. Considering it is already known that peripheral immune cells are altered in colorectal cancer (CRC) patients, this study aims to investigate the changes in lymphocyte subsets in SARIFA-positive cases and correlate these changes with the local immune response.
METHODS: Flow cytometry was performed to analyze B, T, and natural killer (NK) cells in the peripheral blood (PB) of 45 CRC patients. Consecutively, lymphocytes in PB, tumor-infiltrating lymphocytes (TILs), and CD56+ and CD57+ lymphocytes at the invasion front and the tumor center were compared between patients with SARIFA-positive and SARIFA-negative CRCs.
RESULTS: Whereas no differences could be observed regarding most PB lymphocyte populations as well as TILs, NK cells were dramatically reduced in the PB of SARIFA-positive cases. Moreover, CD56 and CD57 immunohistochemistry suggested SARIFA-status-dependent changes regarding NK cells and NK-like lymphocytes in the tumor microenvironment.
CONCLUSIONS: This study proves that our newly introduced biomarker, SARIFA, comes along with distinct immunologic alterations, especially regarding NK cells.
METHODS: Flow cytometry was performed to analyze B, T, and natural killer (NK) cells in the peripheral blood (PB) of 45 CRC patients. Consecutively, lymphocytes in PB, tumor-infiltrating lymphocytes (TILs), and CD56+ and CD57+ lymphocytes at the invasion front and the tumor center were compared between patients with SARIFA-positive and SARIFA-negative CRCs.
RESULTS: Whereas no differences could be observed regarding most PB lymphocyte populations as well as TILs, NK cells were dramatically reduced in the PB of SARIFA-positive cases. Moreover, CD56 and CD57 immunohistochemistry suggested SARIFA-status-dependent changes regarding NK cells and NK-like lymphocytes in the tumor microenvironment.
CONCLUSIONS: This study proves that our newly introduced biomarker, SARIFA, comes along with distinct immunologic alterations, especially regarding NK cells.
摘要：
背景：最近，我们的研究小组引入基质反应性浸润前沿区（SARIFA）作为结肠癌患者预后较差的独立预后预测因子，这可能是基于免疫改变和直接的肿瘤-脂肪细胞相互作用:两者一起反映了不同的肿瘤生物学。考虑到已经知道结直肠癌（CRC）患者的外周血免疫细胞发生改变，本研究旨在探讨SARIFA阳性病例中淋巴细胞亚群的变化,并将这些变化与局部免疫反应相关.
方法：流式细胞术分析B，T,45例CRC患者外周血中的自然杀伤（NK）细胞。连续,PB中的淋巴细胞，肿瘤浸润淋巴细胞（TIL），比较了SARIFA阳性和SARIFA阴性CRCs患者在浸润前沿和肿瘤中心的CD56和CD57淋巴细胞。
结果：尽管在大多数PB淋巴细胞群体和TIL方面没有观察到差异，在SARIFA阳性病例的PB中,NK细胞显著减少。此外，CD56和CD57免疫组织化学提示肿瘤微环境中NK细胞和NK样淋巴细胞的SARIFA状态依赖性变化。
结论：这项研究证明了我们新引入的生物标志物，SARIFA,伴随着不同的免疫学改变，尤其是NK细胞。
方法：流式细胞术分析B，T,45例CRC患者外周血中的自然杀伤（NK）细胞。连续,PB中的淋巴细胞，肿瘤浸润淋巴细胞（TIL），比较了SARIFA阳性和SARIFA阴性CRCs患者在浸润前沿和肿瘤中心的CD56和CD57淋巴细胞。
结果：尽管在大多数PB淋巴细胞群体和TIL方面没有观察到差异，在SARIFA阳性病例的PB中,NK细胞显著减少。此外，CD56和CD57免疫组织化学提示肿瘤微环境中NK细胞和NK样淋巴细胞的SARIFA状态依赖性变化。
结论：这项研究证明了我们新引入的生物标志物，SARIFA,伴随着不同的免疫学改变，尤其是NK细胞。
